Gemma N. Jones et al has recently published in the British Journal of Cancer an article revealing pRAD50 (Ser635) as a pharmacodynamic biomarker of ATM (AZD0156) and ATR inhibitors (AZD6738) to treat cancers. doi:10.1038/s41416-018-0286-4

Key sensors of DNA damage such as ATM and ATR are targets of choice for drug discovery. A useful screening method is based on synthetic lethality. The pre-screening can be done on convenient HeLa cells.

CRISPR/Cas9 is relatively simple to implement, as the researcher fully controls the experimental design of the tools, from the sgRNA sequence to the Cas9 protein.

GeneCopoeia brand products include any possible DNA construct/plasmid in addition to an ever-growing offer of associated products and services. Here is a quick overview of the offer:

If you search for any human or murine gene (e.g. NFKB1) on the GeneCopoeia website, you will get a search result like this one displaying the available catalog products: